Boston Common Asset Management LLC Has $11.80 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Boston Common Asset Management LLC increased its holdings in Edwards Lifesciences Corporation by 11.5%, owning 150,862 shares worth approximately $11.8 million following acquisitions in the second quarter.
• Several hedge funds have adjusted their stakes in EDW, with notable transactions including Merit Financial Group boosting its holdings by 93.4% in the first quarter.
• Analysts have set a target price range for Edwards Lifesciences, with the average target now at $86.61, reflecting favorable ratings from multiple firms such as Goldman Sachs and Wells Fargo.

Boston Common Asset Management LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 11.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 150,862 shares of the medical research company's stock after buying an additional 15,550 shares during the quarter. Boston Common Asset Management LLC's holdings in Edwards Lifesciences were worth $11,799,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $266,000. Merit Financial Group LLC boosted its holdings in Edwards Lifesciences by 93.4% in the first quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company's stock valued at $782,000 after acquiring an additional 5,212 shares during the last quarter. Unique Wealth LLC bought a new position in Edwards Lifesciences in the first quarter valued at about $248,000. Ehrlich Financial Group boosted its holdings in Edwards Lifesciences by 5.7% in the first quarter. Ehrlich Financial Group now owns 10,950 shares of the medical research company's stock valued at $794,000 after acquiring an additional 586 shares during the last quarter. Finally, Radnor Capital Management LLC boosted its holdings in Edwards Lifesciences by 11.1% in the first quarter. Radnor Capital Management LLC now owns 24,070 shares of the medical research company's stock valued at $1,745,000 after acquiring an additional 2,400 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on EW shares. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Morgan Stanley raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the stock a "buy" rating in a report on Monday, September 22nd. Truist Financial raised their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Finally, Wells Fargo & Company raised their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $86.61.

Edwards Lifesciences Trading Up 0.5%

NYSE EW opened at $77.03 on Friday. The firm has a market cap of $45.22 billion, a P/E ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock's 50-day moving average is $78.50 and its 200-day moving average is $75.97. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.